Accolade (ACCD)
(Delayed Data from NSDQ)
$4.34 USD
+0.03 (0.70%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $4.33 -0.01 (-0.23%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth D Momentum D VGM
Price, Consensus and EPS Surprise
ACCD 4.34 +0.03(0.70%)
Will ACCD be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ACCD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ACCD
All You Need to Know About Accolade (ACCD) Rating Upgrade to Buy
Why You Should Retain Xerox (XRX) in Your Portfolio Now
ACCD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Reasons Why Waste Connections (WCN) is an Attractive Pick Now
After Plunging -46.98% in 4 Weeks, Here's Why the Trend Might Reverse for Accolade (ACCD)
After Plunging -47.01% in 4 Weeks, Here's Why the Trend Might Reverse for Accolade (ACCD)
Other News for ACCD
Accolade To Present at Morgan Stanley 22nd Annual Global Healthcare Conference
First-of-its-kind Healthcare Innovation Provides Synchronized, Customized Whole-Health Strategies
Starbucks picks new CEO, Baxter divests Kidney Care segment: Morning Buzz
Accolade’s Growth and Profitability Outlook Underscored by Buy Rating
Accolade gains on report of takeover interest